FDA narrows EUAs for Covid-19 tests, steering companies to traditional review pathways

The FDA said it will review fewer Covid-19 diagnostics for emergency use authorization. The policy update follows an Office of Inspector General report that found the urgency to increase testing availability led to problems, including the authorization of many low-quality tests.